| IV-01 Nikita Sakhanenko New information-theory-based methods in the analysis of childhood development data Thursday 14:40-16:00 |
| IV-03 Celine Sarr Capacities of NPDE, VPC and pvcVPC at detecting model misspecification: a simulation study of a PK model showed no apparent difference Thursday 14:40-16:00 |
| IV-04 Nina Scherer Pharmacokinetic and Pharmacodynamic Modeling of Alirocumab and Evolocumab, two fully human monoclonal antibodies targeting PCSK9 Thursday 14:40-16:00 |
| IV-05 Emilie Schindler PK-PD modeling of VEGF, sVEGFR-1, sVEGFR-2, sVEGFR-3 and tumor size as predictors of overall survival in axitinib-treated metastatic renal cell carcinoma (mRCC) patients Thursday 14:40-16:00 |
| IV-06 Johannes Schropp Development and implementation of drug-drug interaction mechanisms with target-mediated drug disposition Thursday 14:40-16:00 |
| IV-07 Partho Sen Identification of foods with optimal nutritional value through data mining. Thursday 14:40-16:00 |
| IV-08 Ben Small Changes in liver volume – a population-based approach to meta-analysis of paediatric, adult and geriatric populations Thursday 14:40-16:00 |
| IV-09 Kevin Smart Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab Thursday 14:40-16:00 |
| IV-10 Mike K Smith Model Description Language (MDL) - a standard for model communication and interoperability Thursday 14:40-16:00 |
| IV-11 Victor Sokolov A mechanistic PKPD model relating early asthmatic response to anti-leukotriene drug PK and biomarker levels in allergen challenge studies Thursday 14:40-16:00 |
| IV-12 Byungjeong Song Application of different methodologies to explain the pharmacokinetic variabilities in pregnant women: Case study of Sulindac usage Thursday 14:40-16:00 |
| IV-13 Amaia Soraluce Population pharmacokinetics of linezolid in critically ill patients and treatment probability of target attainment Thursday 14:40-16:00 |
| IV-14 Konstantina Soulele A population pharmacokinetic study of salmeterol in asthmatic patients using two dry powder inhalers Thursday 14:40-16:00 |
| IV-15 Spyros Stamatelos High-Resolution Image-based Computational Modeling of Breast Tumor Microvasculature Thursday 14:40-16:00 |
| IV-16 Oleg Stepanov A quantitative systems pharmacology model to explore combination efficacy of immuno-oncology compounds: Effects of CXCR2 and PD-1 inhibitions Thursday 14:40-16:00 |
| IV-17 M. Elena Suarez Gonzalez How delayed or missed doses influence efficacy of amoxicillin in outpatients with community-acquired pneumonia: A pharmacokinetic/pharmacodynamic simulation analysis Thursday 14:40-16:00 |
| IV-18 Siddharth Sukumaran A quantitative systems pharmacology model for evaluating potential drugs for treatment of asthma Thursday 14:40-16:00 |
| IV-19 Robin Svensson Population pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin Thursday 14:40-16:00 |
| IV-20 Eva Sverrisdottir Pharmacokinetic Metamodel of Morphine and Morphine-6-Glucuronide in Neonates and Adults Thursday 14:40-16:00 |
| IV-21 Maciej Swat PharmML & SO - standards for encoding models and results in PMX and QSP Thursday 14:40-16:00 |
| IV-22 Tatiana Yakovleva A systems pharmacology model of SGLT2 and SGLT1 inhibition to understand mechanism and quantification of urinary glucose excretion after treatment with Dapagliflozin, Canagliflozin and Empagliflozin Thursday 14:40-16:00 |
| IV-23 Paulo Teixeira The Effect of Anthropometric Covariates on Clearance of Valproic Acid. Thursday 14:40-16:00 |
| IV-24 Rob ter Heine The influence of erythrocyte accumulation on everolimus pharmacokinetics and pharmacodynamics in cancer patients Thursday 14:40-16:00 |
| IV-25 Adrien Tessier Population Pharmacokinetic modelling and Pharmacogenetic analysis through a penalised regression approach for a molecule S Thursday 14:40-16:00 |
| IV-26 Donato Teutonico Whole-body PBPK/PD modelling of ciprofloxacin and its anti-bacterial activity Thursday 14:40-16:00 |
| IV-27 Hoai-Thu Thai Model-based drug development to support isatuximab dosing regimen selection in Phase II multiple myeloma patients Thursday 14:40-16:00 |
| IV-28 Anders Thorsted Toxicokinetics of Endotoxin and its Induction of Pro-Inflammatory Cytokines Tumor Necrosis Factor a and Interleukin-6 Thursday 14:40-16:00 |
| IV-29 Yingying Tian Population pharmacokinetic analysis of everolimus in patients with solid tumors Thursday 14:40-16:00 |
| IV-30 Huybrecht T'jollyn Pharmacokinetics of galantamine in plasma and brain for different intranasal formulations: an experimental in vivo study Thursday 14:40-16:00 |
| IV-31 Michel Tod Comparison of the mechanistic static in vivo approach to a PBPK approach for prediction of metabolic drug-drug interactions. Thursday 14:40-16:00 |
| IV-32 Bruna Gaelzer Silva Torres Population Pharmacokinetic Modeling of Ciprofloxacin Free Lung Concentrations in Healthy and Pseudomonas aeruginosa Biofilm Infected Wistar Rats Thursday 14:40-16:00 |
| IV-33 Elena Tosca Evaluation of a PK/PD DEB-based model for tumor-in-host growth kinetics under anticancer treatment Thursday 14:40-16:00 |
| IV-34 Mira Tout Rituximab target-mediated elimination is influenced by both baseline antigenic burden and FCGR3A polymorphism in chronic lymphocytic leukemia Thursday 14:40-16:00 |
| IV-35 Mirjam Trame Development of a Mechanism Based Platform to Predict Cardiac Contractility and Hemodynamics in Conscious Dogs Thursday 14:40-16:00 |
| IV-36 Iñaki F. Trocóniz Markov Model for Lithium Compliance Assessment Thursday 14:40-16:00 |
| IV-37 Max Tsai Modelling of Pharmacokinetics and the Incidence of Adverse Events of the PDE-10A Inhibitor TAK-063 Thursday 14:40-16:00 |
| IV-38 Ken-ichi Umehara Assessment of DDI potential of ruxolitinib (INC424), a dual substrate of CYP3A4 and CYP2C9, using a verified PBPK model to support submissions to Health Authorities Thursday 14:40-16:00 |
| IV-39 Moreno Ursino Evaluating phase I studies in small populations when incorporating pharmacokinetic information Thursday 14:40-16:00 |
| IV-40 Muhammad Usman Population Pharmacokinetics of Meropenem in Elderly Patients: Dosing simulations based on Renal Function Thursday 14:40-16:00 |
| IV-41 Vladimir Vainstein Dose translation of a hematopoietic acute radiation syndrome protection agent (recombinant human Interleukin-12) to humans. Thursday 14:40-16:00 |
| IV-42 Pyry Välitalo A mathematical method assessing the informativeness of total test score on the basis of an item response theory model: A case study on pain in children Thursday 14:40-16:00 |
| IV-43 Willem van den Brink Finding underlying longitudinal patterns in pharmaco-metabolomics data Thursday 14:40-16:00 |
| IV-44 Sven van Dijkman Differentiation between Parkinson’s and Parkinson’s-like patients in MDS-UPDRS-based diagnosis Thursday 14:40-16:00 |
| IV-45 Tamara van Donge Evaluating biosimilarity of monoclonal antibodies: comparison of population approach nonlinear mixed effects models to standard non-compartmental analysis Thursday 14:40-16:00 |
| IV-46 Michiel Van Esdonk Development of a semi-population deconvolution method for the analysis of growth hormone profiles Thursday 14:40-16:00 |
| IV-47 Coen van Hasselt The proof is in the pee: Population asparagus urinary odor kinetics. Thursday 14:40-16:00 |
| IV-49 Swantje Völler Dose Recommendations for Recombinant Asparaginase in Children: A Population Pharmacokinetic Analysis Thursday 14:40-16:00 |
| IV-50 Max von Kleist Systems pharmacology pipeline to assess NRTI-efficacy for repurposing as pre-exposure prophylactic compounds against HIV-1 infection Thursday 14:40-16:00 |
| IV-51 Camille Vong Population Pharmacokinetics of Tofacitinib in Induction Studies for Moderate-to-Severe Ulcerative Colitis Patients Thursday 14:40-16:00 |
| IV-52 Veronika Voronova Investigation of the diabetes-related metabolic memory phenomenon using a quantitative systems pharmacology approach Thursday 14:40-16:00 |
| IV-53 Ulrika Wählby Hamrén Pharmacokinetics of the inhaled selective glucocorticoid receptor modulator AZD5423 following inhalation using different devices Thursday 14:40-16:00 |
| IV-55 Siyuan Wang An integrated PK/PD model to link the frequency of cancer-stem-like cells to tumor volume for sunitinib combined with dopamine in the treatment of drug-resistant breast cancer Thursday 14:40-16:00 |
| IV-56 Sebastian Weber Modeling Recurrent Safety Events in Drug Combinations using a Time-Varying Poisson Process Thursday 14:40-16:00 |
| IV-57 Janak Wedagedera Investigating the Importance of Considering Inter-correlations of Cytochrome P450 Enzyme Abundances in Human Liver When Predicting Drug-Drug Interactions Thursday 14:40-16:00 |
| IV-58 Gustaf Wellhagen Carbohydrate intake contribution to HbA1c Thursday 14:40-16:00 |
| IV-59 Thomas Wendl Computational Modelling of Personalized Hemodynamic Response to Valve Replacement Surgery in Heart Failure Patients Thursday 14:40-16:00 |
| IV-60 Pawel Wiczling A Bayesian approach for population pharmacokinetic modeling of dexmedetomidine during long-term infusion in critically ill pediatric patients. Thursday 14:40-16:00 |
| IV-61 Rixt Wijma Population pharmacokinetics of meropenem during intermittent and continuous infusion in healthy volunteers Thursday 14:40-16:00 |
| IV-62 Jayson Wilbur Zika microcephaly cutoffs revisited: A study of Non-parametric methods in fetal growth Thursday 14:40-16:00 |
| IV-63 Julia Winkler Population pharmacokinetics of lacosamide to support intravenous dose adaptation in children with epilepsy Thursday 14:40-16:00 |
| IV-64 Jan-Georg Wojtyniak A cancer cell cycle model to predict effects of combination therapy and different dosing schedules on cell cycle, tumor growth and therapy outcome Thursday 14:40-16:00 |
| IV-65 Dan Wright A population pharmacokinetic model for 51Cr EDTA, an isotopic biomarker for renal function: impact on carboplatin dosing. Thursday 14:40-16:00 |
| IV-66 Xia Li Population pharmacokinetics of multiple oral doses of alcohol in humans using blood and breath measures Thursday 14:40-16:00 |
| IV-67 Gulbeyaz Yildiz Turkyilmaz Investigating the ability of population PK models to characterize secondary exposure parameters Thursday 14:40-16:00 |
| IV-68 Younghoon Yoo Pharmacokinetic Model for subconjunctival injection of bevacizumab in Rabbits. Thursday 14:40-16:00 |
| IV-69 Seonghae Yoon Population pharmacokinetic analysis of oxcarbazepine in patients with epilepsy Thursday 14:40-16:00 |
| IV-70 Huixin Yu Development of a pharmacokinetic model for pazopanib – a tyrosine kinase inhibitor used for the treatment of solid tumours Thursday 14:40-16:00 |
| IV-71 Jurij Aguiar Zdovc Pharmacokinetics of vancomycin in intensive-care patients Thursday 14:40-16:00 |
| IV-72 Fan Zhang Population pharmacokinetic modeling of lamotrigine in Chinese subjects Thursday 14:40-16:00 |
| IV-74 Meng Zhaoling Program-wise trial simulation assessing design and analysis options from proof of concept to dose ranging Thursday 14:40-16:00 |
| IV-75 Chenguang Zhou Semi-mechanistic multiple-analyte pharmacokinetic model for a THIOMAB antibiotic conjugate against Staphylococcus aureus in mouse, rat and monkey Thursday 14:40-16:00 |
| IV-76 Li Zhu Population Pharmacokinetic Modeling of Ulocuplumab, an anti-CXCR4 Monoclonal Antibody in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Multiple Myeloma Thursday 14:40-16:00 |
| IV-77 Kirill Zhudenkov A Markov Chain model to characterize cataract progression and disease burden in the Russian Federation Thursday 14:40-16:00 |
| IV-78 Jochen Zisowsky A Method to Perform PK-QT Analyses When Several Active Compounds or Metabolites Are Present Thursday 14:40-16:00 |
